Literature DB >> 31284301

Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia: A Multihospital Cohort Study.

Valerie M Vaughn1, Scott A Flanders2, Ashley Snyder2, Anna Conlon2, Mary A M Rogers1, Anurag N Malani3, Elizabeth McLaughlin2, Sarah Bloemers2, Arjun Srinivasan4, Jerod Nagel5, Scott Kaatz6, Danielle Osterholzer7, Rama Thyagarajan8, Lama Hsaiky8, Vineet Chopra1, Tejal N Gandhi2.   

Abstract

Background: Randomized trials demonstrate no benefit from antibiotic treatment exceeding the shortest effective duration. Objective: To examine predictors and outcomes associated with excess duration of antibiotic treatment. Design: Retrospective cohort study. Setting: 43 hospitals in the Michigan Hospital Medicine Safety Consortium. Patients: 6481 general care medical patients with pneumonia. Measurements: The primary outcome was the rate of excess antibiotic treatment duration (excess days per 30-day period). Excess days were calculated by subtracting each patient's shortest effective (expected) treatment duration (based on time to clinical stability, pathogen, and pneumonia classification [community-acquired vs. health care-associated]) from the actual duration. Negative binomial generalized estimating equations (GEEs) were used to calculate rate ratios to assess predictors of 30-day rates of excess duration. Patient outcomes, assessed at 30 days via the medical record and telephone calls, were evaluated using logit GEEs that adjusted for patient characteristics and probability of treatment.
Results: Two thirds (67.8% [4391 of 6481]) of patients received excess antibiotic therapy. Antibiotics prescribed at discharge accounted for 93.2% of excess duration. Patients who had respiratory cultures or nonculture diagnostic testing, had a longer stay, received a high-risk antibiotic in the prior 90 days, had community-acquired pneumonia, or did not have a total antibiotic treatment duration documented at discharge were more likely to receive excess treatment. Excess treatment was not associated with lower rates of any adverse outcomes, including death, readmission, emergency department visit, or Clostridioides difficile infection. Each excess day of treatment was associated with a 5% increase in the odds of antibiotic-associated adverse events reported by patients after discharge. Limitation: Retrospective design; not all patients could be contacted to report 30-day outcomes.
Conclusion: Patients hospitalized with pneumonia often receive excess antibiotic therapy. Excess antibiotic treatment was associated with patient-reported adverse events. Future interventions should focus on whether reducing excess treatment and improving documentation at discharge improves outcomes. Primary Funding Source: Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network as part of the BCBSM Value Partnerships program.

Entities:  

Year:  2019        PMID: 31284301     DOI: 10.7326/M18-3640

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  40 in total

Review 1. 

Authors:  Samiha Mohsen; James A Dickinson; Ranjani Somayaji
Journal:  Can Fam Physician       Date:  2020-09       Impact factor: 3.275

2.  Duration and Life-Stage of Antibiotic Use and Risks of All-Cause and Cause-Specific Mortality: Prospective Cohort Study.

Authors:  Yoriko Heianza; Wenjie Ma; Xiang Li; Yin Cao; Andrew T Chan; Eric B Rimm; Frank B Hu; Kathryn M Rexrode; JoAnn E Manson; Lu Qi
Journal:  Circ Res       Date:  2019-12-17       Impact factor: 17.367

3.  Duration of Antibiotic Therapy: Shorter Is Better.

Authors:  Brad Spellberg; Louis B Rice
Journal:  Ann Intern Med       Date:  2019-07-09       Impact factor: 25.391

4.  Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.

Authors:  Laura Evans; Andrew Rhodes; Waleed Alhazzani; Massimo Antonelli; Craig M Coopersmith; Craig French; Flávia R Machado; Lauralyn Mcintyre; Marlies Ostermann; Hallie C Prescott; Christa Schorr; Steven Simpson; W Joost Wiersinga; Fayez Alshamsi; Derek C Angus; Yaseen Arabi; Luciano Azevedo; Richard Beale; Gregory Beilman; Emilie Belley-Cote; Lisa Burry; Maurizio Cecconi; John Centofanti; Angel Coz Yataco; Jan De Waele; R Phillip Dellinger; Kent Doi; Bin Du; Elisa Estenssoro; Ricard Ferrer; Charles Gomersall; Carol Hodgson; Morten Hylander Møller; Theodore Iwashyna; Shevin Jacob; Ruth Kleinpell; Michael Klompas; Younsuck Koh; Anand Kumar; Arthur Kwizera; Suzana Lobo; Henry Masur; Steven McGloughlin; Sangeeta Mehta; Yatin Mehta; Mervyn Mer; Mark Nunnally; Simon Oczkowski; Tiffany Osborn; Elizabeth Papathanassoglou; Anders Perner; Michael Puskarich; Jason Roberts; William Schweickert; Maureen Seckel; Jonathan Sevransky; Charles L Sprung; Tobias Welte; Janice Zimmerman; Mitchell Levy
Journal:  Intensive Care Med       Date:  2021-10-02       Impact factor: 17.440

Review 5.  Update on the adverse effects of antimicrobial therapies in community practice.

Authors:  Samiha Mohsen; James A Dickinson; Ranjani Somayaji
Journal:  Can Fam Physician       Date:  2020-09       Impact factor: 3.275

Review 6.  Antimicrobial Treatment Duration in Sepsis and Serious Infections.

Authors:  Lindsay M Busch; Sameer S Kadri
Journal:  J Infect Dis       Date:  2020-07-21       Impact factor: 5.226

7.  Concordance of antibiotic prescribing with the American Dental Association acute oral infection guidelines within Veterans' Affairs (VA) dentistry.

Authors:  Daniel B Carlsen; Michael J Durkin; Gretchen Gibson; M Marianne Jurasic; Ursula Patel; Linda Poggensee; Margaret A Fitzpatrick; Kelly Echevarria; Jessina McGregor; Charlesnika T Evans; Katie J Suda
Journal:  Infect Control Hosp Epidemiol       Date:  2021-03-02       Impact factor: 3.254

8.  Characterizing Risk Factors for Clostridioides difficile Infection among Hospitalized Patients with Community-Acquired Pneumonia.

Authors:  Caroline C Jozefczyk; W Justin Moore; Paul R Yarnold; Nathaniel J Rhodes; Karolina Harkabuz; Robert Maxwell; Sarah H Sutton; Christina Silkaitis; Chao Qi; Richard G Wunderink; Teresa R Zembower
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

9.  Preparing for the New Joint Commission Requirements: a Model for Tracking Outcomes of an Ambulatory Antibiotic Stewardship Program in Primary Care.

Authors:  Eliana V Hempel; Nicholas Duca; Ryan Kipp; John van Harskamp; Gregory Caputo
Journal:  J Gen Intern Med       Date:  2021-01-08       Impact factor: 5.128

10.  Inpatient and Discharge Fluoroquinolone Prescribing in Veterans Affairs Hospitals Between 2014 and 2017.

Authors:  Valerie M Vaughn; Sarah M Seelye; Xiao Qing Wang; Wyndy L Wiitala; Michael A Rubin; Hallie C Prescott
Journal:  Open Forum Infect Dis       Date:  2020-04-30       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.